Approved indications: In adults, Inlyta is approved for advanced renal cell carcinoma (RCC) as first-line treatment in combination with pembrolizumab or avelumab and as a single agent after failure of one prior systemic therapy.

Off-label uses: Axitinib has been studied in other solid tumors (such as certain liver or thyroid cancers), but these uses are not FDA-approved and are generally limited to clinical trials or highly selected cases guided by oncology specialists.

Efficacy expectations:

• In first-line combinations with pembrolizumab or avelumab, many patients have meaningful tumor shrinkage and significantly longer time before the cancer worsens compared with older standard sunitinib, with some responses lasting years.
• As single-agent second-line therapy, Inlyta typically delays disease progression for several months on average, though some patients have shorter and some longer benefit.
• CT or MRI scans are usually repeated about every 6–12 weeks, and patients who respond often show improvement on the first or second follow-up scan.

Comparison to similar drugs: Inlyta is one of several VEGF-targeting tyrosine kinase inhibitors for RCC; its effectiveness is broadly comparable to other modern agents, and its immunotherapy combinations are considered standard first-line options alongside other TKI–immunotherapy regimens.

Standard adult dosing: The usual starting dose of Inlyta for advanced RCC is 5 mg taken by mouth twice daily, about 12 hours apart, with the same starting dose used whether it is given alone or in combination with pembrolizumab or avelumab.

How to take it: Swallow the tablets whole with a glass of water, do not crush or chew them, and take them consistently with or without food at roughly the same times each day; avoid grapefruit or grapefruit juice and St. John’s wort because they can alter Inlyta levels.

Dose adjustments and special situations: Based on side effects and blood pressure, the dose may be reduced (for example to 3 mg or 2 mg twice daily) or cautiously increased (up to 7 mg or 10 mg twice daily in selected patients who tolerate treatment well), and people with moderate liver impairment usually start at about half the standard dose, while those with more severe liver or kidney problems require individualized specialist guidance.

Missed dose or vomiting: If you miss a dose or vomit after taking Inlyta, do not take an extra tablet; simply take your next scheduled dose at the usual time.

Overdose: If you take more than the prescribed dose, contact your oncology team or Poison Control (1-800-222-1222 in the U.S.) right away, or seek emergency medical care.

Common side effects: The most frequent effects include diarrhea, high blood pressure, fatigue or weakness, decreased appetite, nausea or vomiting, hoarseness (voice changes), hand–foot syndrome (tender, red, or peeling skin on palms and soles), weight loss, and constipation; these often begin in the first weeks of treatment and are usually manageable with supportive care and dose adjustments.

• Mild to moderate side effects are very common, and blood pressure rises are especially expected, so regular blood pressure checks are important.
• Changes in thyroid function and liver blood tests can occur and are usually monitored with periodic lab work.

Serious or rare adverse effects needing urgent attention:

• Severe high blood pressure, chest pain, shortness of breath, sudden weakness, trouble speaking, or vision changes (possible stroke, heart attack, or blood clot).
• Coughing or vomiting blood, black or bloody stools, or other major bleeding.
• Severe abdominal pain, vomiting, or signs of a hole in the stomach or intestines (gastrointestinal perforation or fistula).
• Severe headache, confusion, seizures, or vision changes that may suggest reversible posterior leukoencephalopathy syndrome (RPLS).
• New or worsening swelling, rapid weight gain, or shortness of breath that could indicate heart failure.
• Yellowing of skin or eyes, dark urine, or severe fatigue that may signal liver injury (especially when combined with immunotherapy).

Warnings and precautions: Inlyta can cause or worsen high blood pressure, blood clots, bleeding, heart failure, liver test abnormalities, thyroid problems, and protein in the urine, so patients usually need regular blood pressure checks and periodic blood and urine tests; people with recent serious bleeding, uncontrolled hypertension, recent major surgery, poorly healed wounds, or certain heart or clotting problems may need alternative therapy or very close monitoring.

Pregnancy, breastfeeding, age, and organ function: Inlyta can harm an unborn baby and is not recommended during pregnancy; effective contraception is advised for all people who can become pregnant or can father a child during treatment and for 1 week after the last dose, and breastfeeding should be avoided during treatment and for 2 weeks after the final dose. Safety and effectiveness are not established in children, and dose reduction is recommended in moderate liver impairment, while severe liver disease or very poor kidney function requires specialist assessment before use.

Safety compared with similar drugs: Overall, Inlyta’s safety profile is typical of VEGF-targeting tyrosine kinase inhibitors, with hypertension, diarrhea, fatigue, and hand–foot syndrome being the main issues; when combined with immunotherapies, additional immune-related side effects may occur from the partner drug and are managed with separate guidelines.

Reporting side effects and safety updates: Patients should promptly tell their oncology team about any side effects; in the United States, side effects can also be reported directly to FDA MedWatch (online or by phone) and to the manufacturer (Pfizer), where ongoing safety communications and updated prescribing information are posted.

Key drug interactions: Inlyta is broken down mainly by the liver enzyme CYP3A4/5, so strong inhibitors (such as ketoconazole, itraconazole, clarithromycin, certain HIV protease inhibitors) can raise Inlyta levels and may require a lower Inlyta dose, while strong inducers (such as rifampin, carbamazepine, phenytoin, rifabutin, rifapentine, phenobarbital, and St. John’s wort) can reduce effectiveness and are usually avoided.

Food, alcohol, and supplements: Grapefruit or grapefruit juice should be avoided because they increase Inlyta levels, and St. John’s wort should not be used because it can lower levels; moderate alcohol intake is not absolutely contraindicated but should be discussed with the oncology team, especially in people with liver, heart, or bleeding problems.

Other medicines and procedures: Extra caution is needed when Inlyta is taken with blood thinners (such as warfarin, direct oral anticoagulants, or antiplatelet agents) due to bleeding risk, with other drugs that significantly raise blood pressure, or with medicines that can damage the liver or kidneys; before surgeries or invasive procedures, Inlyta is typically stopped at least a couple of days in advance to reduce bleeding and wound-healing complications.

Conditions requiring special precautions: People with uncontrolled hypertension, recent serious bleeding, a history of blood clots or stroke, heart failure, significant liver disease, unhealed wounds, or recent major surgery need careful evaluation and close monitoring if treated with Inlyta, and alternative options may be preferred in some cases.

Monitoring needs: During therapy, providers usually check blood pressure frequently, and periodically monitor blood counts, liver and kidney function tests, thyroid function, and urine protein; depending on individual risk factors, heart function tests or additional imaging or lab work may also be recommended, especially when Inlyta is combined with immunotherapy.

Q: What is Inlyta used for?
A: Inlyta is an oral targeted therapy used to treat advanced renal cell carcinoma (a type of kidney cancer) in adults, either as first-line treatment with certain immunotherapy drugs or alone after one prior systemic therapy.

Q: How long will I need to stay on Inlyta?
A: Most people continue Inlyta as long as it is controlling the cancer and side effects remain manageable, with treatment often reviewed every few weeks and imaging every few months to decide whether to continue, adjust, or change therapy.

Q: When should I expect to see results?
A: Your doctor will usually repeat CT or MRI scans about 6–12 weeks after starting Inlyta (and then at regular intervals), and if the medicine is working, signs of tumor shrinkage or disease stability often appear on these early follow-up scans.

Q: What if I miss a dose or vomit after taking it?
A: If you miss a dose or vomit shortly after taking Inlyta, do not take an extra tablet; simply wait and take your next dose at the regular scheduled time unless your oncology team gives you different instructions.

Q: Can I drink alcohol while taking Inlyta?
A: Small amounts of alcohol may be acceptable for some people, but because both alcohol and Inlyta can affect the liver and blood pressure, you should discuss alcohol use with your oncology team before drinking.

Q: Is it safe to become pregnant or father a child while on Inlyta?
A: No, Inlyta can harm an unborn baby, so anyone who can become pregnant or can father a child should use effective birth control during treatment and for 1 week after the last dose, and pregnancy or plans for pregnancy should be discussed with the care team.

Storage: Store Inlyta tablets at room temperature 68–77°F (20–25°C), keep them in the original tightly closed container, protect from moisture and excess heat, and always keep out of reach of children and pets.

Disposal: Do not flush Inlyta or throw loose tablets in household trash; instead, ask your pharmacist or oncology team about medicine take-back programs or other local guidance, and caregivers handling unused tablets should avoid direct contact when possible and wash their hands afterward.